	US 11,754,565 B2
	Methods and kits for quantifying the removal of mock virus particles from a purified solution
David Cetlin, Potomac, MD (US); and Arun Dhar, Tucson, AZ (US)
Assigned to MOCKV SOLUTIONS LLC, Rockville, MD (US)
Filed by MockV Solutions, Rockville, MD (US)
Filed on Apr. 17, 2019, as Appl. No. 16/386,327.
Application 16/386,327 is a continuation of application No. 15/456,487, filed on Mar. 11, 2017, granted, now 10,309,963.
Application 15/456,487 is a continuation of application No. 14/481,364, filed on Sep. 9, 2014, granted, now 9,632,087, issued on Apr. 25, 2017.
Claims priority of provisional application 61/875,729, filed on Sep. 10, 2013.
Prior Publication US 2019/0353656 A1, Nov. 21, 2019
Int. Cl. G01N 33/569 (2006.01); A61K 39/23 (2006.01); A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 39/21 (2006.01); C12Q 1/70 (2006.01)

CPC G01N 33/56983 (2013.01) [A61K 39/12 (2013.01); A61K 39/23 (2013.01); A61K 39/21 (2013.01); A61K 2039/5258 (2013.01); C12N 2740/10023 (2013.01); C12N 2750/14023 (2013.01); C12Q 1/701 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/015 (2013.01); G01N 2333/15 (2013.01)]

8 Claims

1. A kit comprising:

a stock solution comprising a modified Mouse Minute Virus (MMV) Mock Viral Particle (MVP), wherein the MMV MVP is a non-infectious, non-replicating assembled unit comprising a MMV VP2 viral capsid protein comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 6, wherein said stock solution comprises at least 1×10¹⁰MMV MVP/ml of said MMV MVP and wherein non-MMV MVP proteins are less than 25% of all proteins in the stock solution.